R1 Immunotherapy Fellow @NCI_SurgOncFel || PGY-3 Surgery Resident @NJMSDeptSurg || @RWJMS
Bethesda, MD
Joined March 2022
- Tweets10
- Following159
- Followers72
- Likes16
Maria Fencer retweeted
There hasn't previously been a treatment vs pancreatic cancer this successful. Striking improved (a > doubling) survival results @NEJM and @ASCO today with daraxonrasib, which also became available via an FDA approved early access program and began shipping to physicians this week @RevMedicines
nejm.org/doi/full/10.1056/NE…
Maria Fencer retweeted
ASCO this year has 5,000+ abstracts.
But maybe 24 will actually change practice. This is that map.
(ERRATA: this plot fixes an error on VICTORIA which reflected incorrect data, thnx @Dr_RShatsky)
Map spans 12 disease areas, 24 critical readouts, 5 plenaries & 2 confirmed misses already on the board.
Few things jump out immediately:
▫️Pancreatic cancer gets the headline.
Daraxonrasib: 13.2 vs 6.7 months.
▫️Sarcoma gets a plenary because public science funded what pharma would not.
▫️Lung cancer remains the most crowded battlefield in oncology:
RET adjuvant, bispecific OS, post-osimertinib, next-gen EGFR.
By next week, some of these cells will become new standards of care.
This is your cheat sheet to keep score in real time.
- - - - -
Sources: @asco @OncLive @CancerNetwrk via @Jori_health
- - - - -
Maria Fencer retweeted
The biggest cancer results from ASCO this week, ranked by how much they change a patient’s odds.
1. Colon cancer (BRAF-mutant): the combination doubled survival. Median 30.3 months vs 15.1 on the old standard. BREAKWATER. New standard of care.
2. Lung cancer (ALK+): five years out, 60% of patients on lorlatinib still hadn’t progressed. On the old drug, 8%. CROWN.
3. Lung cancer (EGFR+): amivantamab plus lazertinib cut the risk of death 25% vs the previous best pill. MARIPOSA.
4. Breast cancer (PIK3CA-mutant): gedatolisib hit its primary survival mark, beating the current targeted drug. VIKTORIA-1. Full numbers drop this week.
5. Prostate cancer (high-risk): apalutamide before surgery, the plenary headline. First efficacy readout lands this week.
6. Breast cancer (ER+): SERENA-6, the blood-test-guided drug switch, reports next.
Five years ago, half of these patients had almost nothing.
Maria Fencer retweeted
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
Maria Fencer retweeted
That sound you hear is the culture of American surgery breaking—in preparation to be rebuilt for the better.
More healthy, more vulnerable, and more human.
Thank you to @lubitz_carrie for the most important Presidential address I’ve had the opportunity to hear.
#ASC2023
Maria Fencer retweeted
In a new @womenspowergap report, @RutgersU was identified as a national leader among higher education institutions for the representation of women in leadership roles, ranking 13th out of 130 universities.
I had a great evening exploring the new innovations in breast surgery. Thank you @ASBrS for the opportunity to showcase my research regarding PALB2, CHEK2, and ATM gene mutations. #ASBrS2022
Maria Fencer retweeted
Honored to have our work on the interplay of age and frailty in predicting failure-to-rescue after GI cancer surgery included at #SSO2022. Thanks to excellent mentorship by Dr. David August and other great minds @CDavisMD @MariaFencer @HenryPittMD @RutgersCancer @RWJMS
